1994 …2024
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2019 2024

Research Output 1994 2019

Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort

Varma, P., Rajadurai, A., Holt, D. Q., Devonshire, D. A., Desmond, C., Swan, M. P., Nathan, D., Shelton, E., Prideaux, L., Sorrell, C., Rusli, F., Crantock, L. RF., Dev, A., Ratnam, D., Pianko, S. & Moore, G., 1 Jun 2019, In : Internal Medicine Journal. 49, 6, p. 753-760 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 – final results of the REV1TAL study

Lubel, J., Strasser, S., Stuart, K. A., Dore, G., Thompson, A., Pianko, S., Bollipo, S., Mitchell, J. L., Fragomeli, V., Jones, T., Chivers, S., Gow, P., Iser, D., Levy, M., Tse, E., Gazzola, A., Cheng, W., Nazareth, S., Galhenage, S., Wade, A. & 8 othersWeltman, M., Wigg, A., MacQuillan, G., Sasadeusz, J., George, J., Zekry, A., Roberts, S. K. & the Australian Liver Association Clinical Research Network (ALA CRN), 2017, In : Antiviral Therapy. 22, 8, p. 699-710 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Gane, E. J., Pianko, S., Roberts, S. K., Thompson, A. J., Zeuzem, S., Zuckerman, E., Ben-Ari, Z., Foster, G. R., Agarwal, K., Laursen, A. L., Gerstoft, J., Gao, W., Huang, H. C., Fitzgerald, B., Fernsler, D., Li, J. J., Grandhi, A., Liu, H., Su, F. H., Wan, S. & 11 othersZeng, Z., Chen, H. L., Dutko, F. J., Nguyen, B. Y. T., Wahl, J., Robertson, M. N., Barr, E., Yeh, W. W., Plank, R. M., Butterton, J. R. & Esteban, R., 1 Nov 2017, In : The Lancet Gastroenterology and Hepatology. 2, 11, p. 805-813 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection

Foster, G. R., Pianko, S., Brown, A., Forton, D. M., Nahass, R. G., George, J., Barnes, E., Brainard, D., Massetto, B., Lin, M., Han, B., McHutchison, J. G., Subramanian, G. M., Cooper, C. & Agarwal, K., 2015, In : Gastroenterology. 149, 6, p. 1462 - 1470 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 Hepatitis c virus infection

Pianko, S., Flamm, S. L., Shiffman, M. L., Kumar, S., Strasser, S. I., Dore, G. J., McNally, J., Brainard, D., Han, L., Doehle, B., Mogalian, E., McHutchison, J. G., Rabinovitz, M., Towner, W. J., Gane, E. J., Stedman, C. A. M., Reddy, K. R. & Roberts, S. K., 2015, In : Annals of Internal Medicine. 163, 11, p. 809 - 817 9 p.

Research output: Contribution to journalArticleResearchpeer-review